Lung cancer is the leading cause of cancer-related mortality not only in the United States but
also around the world. In North America, lung cancer has become more predominant among …

Evolving studies with several different targeted therapeutic agents are demonstrating that
patients with genomic alterations of the target, including amplification, translocation and …

Epigenetic alterations are strongly associated with the development of cancer. We
conducted a phase I/II trial of combined epigenetic therapy with azacitidine and entinostat …

Purpose Patients with advanced pancreatic cancer have a poor prognosis and there have
been no improvements in survival since the introduction of gemcitabine in 1996. Pancreatic …

Background This placebo-controlled phase III study investigated the effect on survival of
gefitinib as second-line or third-line treatment for patients with locally advanced or metastatic …

Purpose Epidermal growth factor receptor (EGFR) mutations have been associated with
tumor response to treatment with single-agent EGFR inhibitors in patients with relapsed non …

The'magic bullet'concept of specifically targeting cancer cells at the same time as sparing
normal tissues is now proven, as several monoclonal antibodies and targeted small …

Purpose Erlotinib is a potent reversible HER1/epidermal growth factor receptor (EGFR)
tyrosine kinase inhibitor with single-agent activity in patients with non–small-cell lung cancer …

Background: Gefitinib is a selective inhibitor of the epidermal growth factor (EGFR) tyrosine
kinase, which is overexpressed in many cancers, including non–small-cell lung cancer …

Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors gefitinib and erlotinib are
effective therapies for non–small cell lung cancer patients whose tumors harbor somatic …